Matthew Balk serves as Executive at AzurRx BioPharma, Inc., where they oversee executive responsibilities. Since joining the company, Matthew Balk has executed 4 insider transactions totaling $1.0M, demonstrating a bearish approach to their equity position. Their most recent transaction on Jun 30, 2017 involved selling 100,000 shares valued at $300.0K.
Matthew Balk currently holds 1,787,796 shares of AzurRx BioPharma, Inc. (AZRX), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Matthew Balk has been a net seller of AZRX stock. They have purchased $0 and sold $1.0M worth of shares.
Matthew Balk's most recent insider trade was on Jun 30, 2017, when they sold 100,000 shares at $3.00 per share.
Get notified when new Form 4 filings are submitted
| $3.50 |
| Discretionary |
| Jun 30, 2017 | AZRX | $210.0K | Sale | 60,000 | $3.50 | Discretionary |
| Jun 30, 2017 | AZRX | $300.0K | Sale | 100,000 | $3.00 | Discretionary |